Navigation Links
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
Date:9/29/2008

-- Company Also Announces Participation in Upcoming Investor Conferences in

October --

SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for October 2008, which includes six data presentations and one sponsored symposium at The Obesity Society Annual Scientific Meeting, as well as upcoming corporate presentations at noteworthy investor conferences.

The Obesity Society Annual Scientific Meeting, Phoenix Convention Center

Saturday, October 4

Poster Presentation

Abstract: 317-P

Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the

Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk

Subjects"

Time: 5:00-7:00 p.m. MT

Sunday, October 5

Symposium

Event Code: E1280

Title: "Reward and Obesity; Too Much of a Good Thing?"

Time: 6:15-7:45 a.m. MT

Location: Hyatt Regency Phoenix, Regency Ballroom A/B

Oral Presentation

Abstract: 61-OR

Presenter: Ronald Landbloom, M.D.

Title: "Long Term Weight Loss from a Dose Optimization Study with

Zonisamide SR and Bupropion SR"

Time: 11:00-11:15 a.m. MT

Poster Presentation

Abstract: 585-P

Title: "Relative Bioavailability of Sustained-release (SR) versus

Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese

Volunteers: Implications for Improved Tolerability?"

Time: 5:30-7:30 p.m. MT

Monday, October 6

Oral Presentation

Abstract: 104-OR

Presenter: Sonja K. Billes, Ph.D.

Title: "Leptin Regulates Food Intake Via Dopamine Receptor-Dependent

Mechanisms"

Time: 11:30-11:45 a.m. MT

Poster Presentation

Abstract: 847-P

Title: "Quality of Life Improvements from a Dose Optimization Study with

Zonisamide SR and Bupropion SR"

Time: 12:45-2:45 p.m. MT

Poster Presentation

Abstract: 848-P

Title: "Timing of Response from a Dose Optimization Study with Zonisamide

SR and Bupropion SR"

Time: 12:45-2:45 p.m. MT

Upcoming Corporate Presentations

JMP Securities Healthcare Sector Focus Conference

Le Parker Meridien, New York

October 6, 2008

10:00 a.m. ET

BIOCOM Investor Conference

Hyatt Regency La Jolla, San Diego

October 28, 2008

4:00 p.m. PT

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):